About The Peptide Table
We grade 56 compounds on completed randomized human trials. We name no seller and print no doses.
What do we do?
What do we leave out?
We name no seller, rank none and link to none. We print no doses and no instructions for use. We give no personal medical advice, and we never pair a compound with a health promise. There is no shop and no checkout anywhere on the site.
How are the facts checked?
Drafts are written with AI assistance. Each record lists its sources and the date it was last checked. Corrections are public, on the Corrections page. We never attribute a byline to an AI system.
How do we grade?
We count completed randomized human trials and grade each compound on that human evidence, from A to D. Approval is its own fact and sits beside the grade. The full rule is on the page How we count a trial.
| Grade | Label | What it means |
|---|---|---|
| Grade A | Large trials | Several completed randomized trials of a health outcome, at the scale that supports an approval |
| Grade B | Some trials | At least one completed randomized trial of a health outcome |
| Grade C | Small studies | Randomized studies that only measured the body's response |
| Grade D | No randomized trial | No completed randomized human trial. Case reports or uncontrolled studies at most |
Where do the facts come from?
We track trial records on ClinicalTrials.gov, approval and compounding status with the FDA, and marketing authorisations with the EMA. Where a record is silent, we say so. A source that is not a primary document is marked “Secondary” on the record.
Sources on the records: ClinicalTrials.gov, PubMed, the FDA and the EMA. Few records link a WADA document yet.
Ask better questions.
One email on Wednesdays: which records changed and the source behind each change, plus one claim checked. Quiet weeks say so in one line. Four minutes. Free.